秋风送爽，丹桂飘香。近日（9月19日-22日），由中华医学会、中华医学会神经病学分会主办，河南省医学会承办的“中华医学会第二十七次神经病学学术会议”在美丽的郑州顺利召开。国内外知名专家学者齐聚，共享学术饕餮盛宴。神经病理性疼痛（NP）指由躯体感觉系统 ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Neuropathic pain is a severe clinical condition caused by damage to the nervous system. It often feels like a burning, ...

Neuropathic pain is a severe clinical condition caused by damage to the nervous system. It often feels like a burning, shooting, tingling ice or stabbing sensation. Conditions such as diabetes or ...

The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...

Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic ...

Neuropathic pain is a chronic and debilitating condition that impacts around 10% of the population in both the United States and Europe. Despite advances in understanding the mechanisms of neuropathic ...

European researchers have mapped the most comprehensive phenotyping of neuropathic pain and identified genetic markers associated with this serious condition.

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused ...